https://www.selleckchem.com/pr....oducts/namodenoson-c
Much is known about the acute infective process of SARS-CoV-2, the causative virus of the COVID-19 pandemic. The marked inflammatory response and coagulopathic state in acute SARS-CoV-2 may promote pulmonary fibrosis. However, little is known of the incidence and seriousness of post-COVID pulmonary pathology. We describe respiratory recovery and self-reported health following infection at time of outpatient attendance. Infection severity was graded into three groups (i) not requiring admission, (ii) requiring hospital admissi
Like
Comment
Share
